Zenios Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Yaqrit Discovery Ltd: Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure Orally-administered, non-absorbable engineered carbon, Carbalive , was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation associated with decompensated cirrhosis Safety of novel dual filtration system, Dialive , confirmed with liver failure patients more likely to see organ failure resolved and more quickly than control group London, UK, 7 January 2021 - Yaqrit, a clinical st...

Yaqrit Discovery Ltd Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure  Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure  Preliminary results from Carbalive and Dialive trials signal potential for new therapies to treat decompensated cirrhosis and reverse liver failure  Orally-administered, non-absorbable engineered carbon, Carbalive ™, was safe, tolerable and showed trends in improvements in...

The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive Safety of novel liver dialysis device confirmed Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03) Significant improvements in mechanistic biomarkers of how Dialive improves organ function 7 th January 2021 - The ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patient...

(2) The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis Patients treated with orally-administered, non-absorbable engineered carbon of controlled porosity was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation The mechanism of this effect is modulation of dysbiosis, gut inflammation and leaky gut that are characteristic of cirrhosis Planning for pivotal trials to support approval in Europe is now under way 7 th January, 2021 - The CARBALIVE Co...